By Ethan Covey
Interim data from the CDC show that nirsevimab-alip (Beyfortus, Sanofi) is highly effective in reducing infants’ risk for hospitalization for respiratory syncytial virus (RSV) infection.
Nirsevimab, a long-acting monoclonal antibody, was recommended by the CDC’s Advisory Committee on Immunization Practices (ACIP) in August 2023, to protect infants ages 8 months and younger against RSV-associated lower respiratory tract infection during their first RSV season. Currently,